FDA Greenlights Lutetium Lu177 Vipivotide Tetraxetan Combined with Androgen Receptor Pathway Inhibitors for Treating Metastatic Prostate Cancer with Unknown or Known Androgen Sensitivity

FDA Greenlights Lutetium Lu177 Vipivotide Tetraxetan Combined with Androgen Receptor Pathway Inhibitors for Treating Metastatic Prostate Cancer with Unknown or Known Androgen Sensitivity